Our study “Comparative effectiveness of the BNT162b2 vs ChAdOx1 vaccine against Covid-19” is available and awaiting feedback at @medrxivpreprint . A short 🧵 medrxiv.org/content/10.110…
1/3- We analysed 235,181 UK Biobank participants aged 50 years or older and vaccinated with one or two doses of BNT162b2 or ChAdOx1. Follow up run until 18/10/2021. IPW weighting was used to minimise confounding, & negative control outcomes to rule out residual bias
2/3 - RESULTS: Compared w ChAdOx1, BNT162b2 was associated with 30% lower risks of both SARS-CoV-2 infection and #COVID19 hospitalisation. Findings were consistent across several subgroups and persisted for at least six months, suggesting no differential waning between vaccines
3/3 - This is a top piece of work by my students @XieJunqing @xtlxt @MedDevEpi in collaboration w @estergeama
• • •
Missing some Tweet in this thread? You can try to
force a refresh
